Radiolabeled Antibody-Drug Conjugates in the Treatment of Solid Tumors [0.03%]
放射性标记的抗体药物偶联物在实体瘤治疗中的应用
Ismaheel O Lawal,Sofiullah Abubakar,Honest Ndlovu et al.
Ismaheel O Lawal et al.
Antibody-drug conjugates (ADCs) utilize monoclonal antibodies (mAbs) that target tumor-specific antigens to deliver potent cytotoxic chemotherapy payloads to the tumor, while sparing normal tissues. The chemotherapy agents employed in ADCs ...
Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access [0.03%]
放射诊疗的实施：挑战、障碍及国际原子能机构驱动的可持续获取策略
Akram Al-Ibraheem,Anita Brink,Sze Ting Lee et al.
Akram Al-Ibraheem et al.
Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted radiotherapy in a single, personalized approach. Over the past decade, the field has gained s...
The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors [0.03%]
177卢±生长抑素类似物-tetraxetan在生长抑素受体阳性神经内分泌肿瘤中的作用
Kalyan Mansukhbhai Shekhda,Shaunak Navalkissoor
Kalyan Mansukhbhai Shekhda
Peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor with receptor agonists has emerged as a key treatment in the management of well-differentiated neuroendocrine tumors (NETs). The therapeutic efficacy of these ...
GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy [0.03%]
_GRPR在转移性癌症中的表达：GRPR放射配体治疗潜在应用述评_
Aurélien Callaud,Heying Duan,Elif Hindié et al.
Aurélien Callaud et al.
Gastrin-Releasing Peptide Receptor (GRPR) represents a promising molecular target for radionuclide therapy (TRT) across a variety of malignancies due to its overexpression in several tumor types, including prostate, breast, lung, melanoma, ...
Letter from the Editors [0.03%]
编者来信
Kirsten Bouchelouche,M Michael Sathekge
Kirsten Bouchelouche
Honest Ndlovu,Ismaheel O Lawal,Kgomotso M G Mokoala et al.
Honest Ndlovu et al.
The diagnosis of infection is crucial in-patient survival, prevention of prolonged hospitalization and undue morbidity and mortality. This can be achieved using various tools target at the specific microbes or the host immune response compo...
PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update [0.03%]
前列腺癌以外的实体瘤中针对PSMA的正电子发射断层扫描影像技术最新研究进展
Nozipho Nyakale,Alex Maes,Mike Sathekge et al.
Nozipho Nyakale et al.
Prostate-specific membrane antigen (PSMA) has been previously shown to be over-expressed on newly formed vessels of a wide variety of solid tumors other than prostate carcinoma. Accordingly, the potential role of PSMA-targeted positron emit...
Artificial Intelligence for Tumor [18F]FDG PET Imaging: Advancements and Future Trends - Part II [0.03%]
肿瘤[F-18]FDG PET imaging的人工智能：进展与未来趋势（第二部分）
Alireza Safarian,Seyed Ali Mirshahvalad,Abolfazl Farbod et al.
Alireza Safarian et al.
The integration of artificial intelligence (AI) into [18F]FDG PET/CT imaging continues to expand, offering new opportunities for more precise, consistent, and personalized oncologic evaluations. Building on the foundation established in Par...
The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal Carcinoma [0.03%]
FAPI显像的临床意义：肝细胞癌、胆管细胞癌、不明原发灶癌症及腹膜癌
Emil Novruzov,Eduards Mamlins,Yuriko Mori et al.
Emil Novruzov et al.
In recent years, FAP-targeted imaging has emerged as a highly-promising modality as a pan-cancer agent. Until now, several studies and review articles have focused on efficacy of FAPI imaging in epithelial malignancies with a high global in...
Radiotracing the Future: Non-FDG Radiotracers Nuclear Medicine [0.03%]
放射性 tracing 未来：非氟脱氧葡萄糖放射性示踪剂核医学
Giuseppe Arturo Fuso,Gianfilippo Bianciardi,Riccardo Mei et al.
Giuseppe Arturo Fuso et al.
Positron Emission Tomography/Computed Tomography (PET/CT) is an advanced hybrid imaging modality that synergistically combines metabolic and anatomical data, revolutionizing diagnostic accuracy and therapeutic monitoring in various patholog...